バイオシミラーの世界市場

Report Highlights

The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.

世界のバイオシミラー市場は、2023 年に 238 億ドルと評価されました。この市場は、2024 年の 285 億ドルから 2029 年には 692 億ドルに成長し、2024 年から 2029 年にかけて年平均成長率 (CAGR) は 19.4% になると予想されています。

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

このレポートは、バイオシミラーの現在および将来の市場の可能性と、2029 年までの市場予測を提供します。また、バイオシミラー市場の推進要因、制約、機会の詳細な分析も含まれています。レポートでは、バイオシミラー業界の競争環境についても取り上げ、製品分析も行っています。

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization’s business segments, financials, product portfolios and recent developments.

Report Synopsis

Report Includes

– 142 data tables and 74 additional tables

– An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029

– Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region

– Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors

– Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product

– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses

– An analysis of key patent publications, grants and applications in biosimilars

– Analysis of the competitive landscape featuring companies’ market shares, strategic alliances, M&A activity and a venture funding outlook

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies

– Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Insights

Chapter 2 Market Overview

Introduction

Terminology of Biosimilars

Key Terms in Biosimilars

WHO Guidelines on Evaluation of Biosimilars

Pharmacovigilance/Post-Approval Monitoring

Biosimilars Vs. Biobetters

Popular Types of Biosimilars

Recombinant Hormones

Recombinant Growth Factors

Monoclonal Antibodies (mAbs)

Fusion Proteins

Interferons

Low Molecular Weight Heparins (LMWHs)

Chapter 3 Market Dynamics

Introduction

Market Drivers

Patent Expirations of Major Biologics

Cost-effectiveness and Healthcare Savings

Market Restraints

Intellectual Property and Legal Issues

Manufacturing and Supply Chain Complexities

Market Opportunities

Increasing Access, Adoption and Awareness

Emerging Markets

Chapter 4 Emerging Technologies

Advanced Analytical Techniques

Single-use Bioreactors

Cell Line Engineering and Expression Systems

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown

Global Biosimilars Market, by Product Type

Monoclonal Antibodies

Recombinant Growth Factors

Recombinant Hormones

Fusion Protein

Others

Global Biosimilars Market, by Therapeutic Application

Cancer and Related Disorders

Autoimmune and Inflammatory Diseases

Diabetes

Anemia

Growth Hormone Deficiency

Other Diseases

Geographic Breakdown

Global Biosimilars Market, by Region

Market Size and Forecast

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 6 Competitive Landscape and Patent Analysis

Overview

Key Market Leaders

Emerging Players

Strategic Analysis

Challenges and Future Trends

Patent Analysis

Patent Regulations in Favor of Branded Biologics

Market Exclusivity

Chapter 7 Regulatory Aspects

Overview

Biosimilar Regulations in Europe

Biosimilar Regulations in the U.S.

Principle of Exclusivity

Biosimilar Regulations in China

Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective

Introduction to ESG

ESG Performance in the Market

ESG Practices in the Biosimilars Industry

Environmental Performance

Concluding Remarks from BCC Research

Chapter 9 Appendix

Research Methodology

Sources

Abbreviations

Company Profiles

ACCORD BIOPHARMA INC.

ALVOTECH

AMGEN INC.

AMNEAL PHARMACEUTICALS LLC.

BIOCON BIOLOGICS LTD.

BIOGEN

CELLTRION INC.

COHERUS BIOSCIENCES

FRESENIUS KABI AG

LILLY

PFIZER INC.

SAMSUNG BIOEPIS

SANDOZ GROUP AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

VIATRIS INC.

List of Tables

Summary Table : Global Biosimilars Market, by Region, Through 2029

Table 1 : Differences Between Generic and Biosimilar Drugs

Table 2 : Terminology Related to Biosimilars

Table 3 : Biosimilars Vs. Biobetters

Table 4 : Examples of Approved Biobetters

Table 5 : Representative Biobetters in Clinical Trials

Table 6 : Key Developments in Biosimilar Recombinant Hormones

Table 7 : Key Developments in Biosimilar Recombinant Growth Factors

Table 8 : Key Developments in Biosimilar Monoclonal Antibodies

Table 9 : Key Developments in Enbrel (Etanercept) Biosimilars

Table 10 : Key Developments in Biosimilar Interferons

Table 11 : Key Developments in LMWHs Biosimilars

Table 12 : Global Biosimilars Market, by Product Type, Through 2029

Table 13 : EMA Approved Biosimilar Monoclonal Antibodies

Table 14 : FDA Approved Biosimilar Monoclonal Antibodies

Table 15 : Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029

Table 16 : Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 17 : Global Trastuzumab Biosimilars Market, by Region, Through 2029

Table 18 : Global Rituximab Biosimilars Market, by Region, Through 2029

Table 19 : Global Adalimumab Biosimilars Market, by Region, Through 2029

Table 20 : Global Bevacizumab Biosimilars Market, by Region, Through 2029

Table 21 : Global Infliximab Biosimilars Market, by Region, Through 2029

Table 22 : EMA Approved Recombinant Growth Factors Biosimilars

Table 23 : FDA Approved Recombinant Growth Factors Biosimilars

Table 24 : Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029

Table 25 : Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 26 : Global Filgrastim Biosimilars Market, by Region, Through 2029

Table 27 : Global Epoetin Alfa Biosimilars Market, by Region, Through 2029

Table 28 : Global Pegfilgrastim Biosimilars Market, by Region, Through 2029

Table 29 : EMA Approved Recombinant Hormones Biosimilars

Table 30 : FDA Approved Recombinant Hormones Biosimilars

Table 31 : Global Recombinant Hormones Biosimilars Market, by Region, Through 2029

Table 32 : Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 33 : Global Insulin Biosimilars Market, by Region, Through 2029

Table 34 : Global Somatotropin Biosimilars Market, by Region, Through 2029

Table 35 : Global Teriparatide Biosimilars Market, by Region, Through 2029

Table 36 : Global Follitropin Alfa Biosimilars Market, by Region, Through 2029

Table 37 : Global Fusion Protein Biosimilars Market, by Region, Through 2029

Table 38 : Global Other Biosimilars Market, by Region, Through 2029

Table 39 : Global Biosimilars Market, by Therapeutic Application, Through 2029

Table 40 : Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029

Table 41 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029

Table 42 : Global Diabetes Market in Biosimilars, by Region, Through 2029

Table 43 : Global Anemia Market in Biosimilars, by Region, Through 2029

Table 44 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029

Table 45 : Global Other Diseases Market in Biosimilars, by Region, Through 2029

Table 46 : Global Biosimilars Market, by Region, Through 2029

Table 47 : North American Biosimilars Market, by Country, Through 2029

Table 48 : North American Biosimilars Market, by Product Type, Through 2029

Table 49 : North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 50 : North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 51 : North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 52 : North American Biosimilars Market, by Therapeutic Application, Through 2029

Table 53 : Biosimilar Approvals in the U.S.

Table 54 : U.S. Biosimilars Market, by Product Type, Through 2029

Table 55 : U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 56 : U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 57 : U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 58 : U.S. Biosimilars Market, by Therapeutic Application, Through 2029

Table 59 : Canadian Biosimilars Market, by Product Type, Through 2029

Table 60 : Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 61 : Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 62 : Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 63 : Canadian Biosimilars Market, by Therapeutic Application, Through 2029

Table 64 : Mexican Biosimilars Market, by Product Type, Through 2029

Table 65 : Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 66 : Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 67 : Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 68 : Mexican Biosimilars Market, by Therapeutic Application, Through 2029

Table 69 : Biosimilar Approvals in Europe

Table 70 : European Biosimilars Market, by Country, Through 2029

Table 71 : European Biosimilars Market, by Product Type, Through 2029

Table 72 : European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 73 : European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 74 : European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 75 : European Biosimilars Market, by Therapeutic Application, Through 2029

Table 76 : German Biosimilars Market, by Product Type, Through 2029

Table 77 : German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 78 : German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 79 : German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 80 : German Biosimilars Market, by Therapeutic Application, Through 2029

Table 81 : U.K. Biosimilars Market, by Product Type, Through 2029

Table 82 : U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 83 : U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 84 : U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 85 : U.K. Biosimilars Market, by Therapeutic Application, Through 2029

Table 86 : French Biosimilars Market, by Product Type, Through 2029

Table 87 : French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 88 : French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 89 : French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 90 : French Biosimilars Market, by Therapeutic Application, Through 2029

Table 91 : Italian Biosimilars Market, by Product Type, Through 2029

Table 92 : Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 93 : Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 94 : Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 95 : Italian Biosimilars Market, by Therapeutic Application, Through 2029

Table 96 : Spanish Biosimilars Market, by Product Type, Through 2029

Table 97 : Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 98 : Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 99 : Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 100 : Spanish Biosimilars Market, by Therapeutic Application, Through 2029

Table 101 : Rest of European Biosimilars Market, by Product Type, Through 2029

Table 102 : Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 103 : Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 104 : Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 105 : Rest of European Biosimilars Market, by Therapeutic Application, Through 2029

Table 106 : Asia-Pacific Biosimilars Market, by Country, Through 2029

Table 107 : Asia-Pacific Biosimilars Market, by Product Type, Through 2029

Table 108 : Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 109 : Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 110 : Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 111 : Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029

Table 112 : Biosimilar Approvals in China

Table 113 : Chinese Biosimilars Market, by Product Type, Through 2029

Table 114 : Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 115 : Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 116 : Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029

Table 117 : Chinese Biosimilars Market, by Therapeutic Application, Through 2029

Table 118 : Japanese Biosimilars Market, by Product Type, Through 2029

Table 119 : Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 120 : Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 121 : Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 122 : Japanese Biosimilars Market, by Therapeutic Application, Through 2029

Table 123 : Indian Biosimilars Market, by Product Type, Through 2029

Table 124 : Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 125 : Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 126 : Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 127 : Indian Biosimilars Market, by Therapeutic Application, Through 2029

Table 128 : Australian Biosimilars Market, by Product Type, Through 2029

Table 129 : Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 130 : Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 131 : Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 132 : Australian Biosimilars Market, by Therapeutic Application, Through 2029

Table 133 : South Korean Biosimilars Market, by Product Type, Through 2029

Table 134 : South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 135 : South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 136 : South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 137 : South Korean Biosimilars Market, by Therapeutic Application, Through 2029

Table 138 : Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029

Table 139 : Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 140 : Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 141 : Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 142 : Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029

Table 143 : RoW Biosimilars Market, by Product Type, Through 2029

Table 144 : RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 145 : RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 146 : RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 147 : RoW Biosimilars Market, by Therapeutic Application, Through 2029

Table 148 : Select Strategic Alliances in the Biosimilars Industry, 2022-2024

Table 149 : Leading Biosimilars Companies, by Revenue, 2023

Table 150 : U.S. Patent Expirations and Biosimilars, 2024

Table 151 : Pending Biosimilar Patent Litigation, 2024

Table 152 : FDA Guidelines on Biosimilars, February 2021

Table 153 : Biosimilar Products Approved in China, 2024

Table 154 : Key Focus Areas in ESG Metrics

Table 155 : ESG Rankings for Key Players in Biosimilars Market, 2024*

Table 156 : Information Sources in This Report

Table 157 : Glossary of Terms Used in the Biosimilars Market

Table 158 : Accord BioPharma Inc.: Company Snapshot

Table 159 : Accord BioPharma Inc.: Product Portfolio

Table 160 : Accord BioPharma Inc.: News/Key Developments, 2024

Table 161 : Alvotech: Company Snapshot

Table 162 : Alvotech: Financial Performance, FY 2022 and 2023

Table 163 : Alvotech: Product Portfolio

Table 164 : Alvotech: News/Key Developments, 2024

Table 165 : Amgen Inc.: Company Snapshot

Table 166 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 167 : Amgen Inc.: Product Portfolio

Table 168 : Amgen Inc.: News/Key Developments, 2022-2023

Table 169 : Amneal Pharmaceuticals LLC.: Company Snapshot

Table 170 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023

Table 171 : Amneal Pharmaceuticals LLC.: Product Portfolio

Table 172 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024

Table 173 : Biocon Biologics Ltd.: Company Snapshot

Table 174 : Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023

Table 175 : Biocon Biologics Ltd.: Product Portfolio

Table 176 : Biocon Biologics Ltd.: News/Key Developments, 2022-2024

Table 177 : Biogen: Company Snapshot

Table 178 : Biogen: Financial Performance, FY 2022 and 2023

Table 179 : Biogen: Product Portfolio

Table 180 : Biogen: News/Key Developments, 2023-2024

Table 181 : Celltrion Inc.: Company Snapshot

Table 182 : Celltrion Inc.: Financial Performance, FY 2022 and 2023

Table 183 : Celltrion Inc.: Product Portfolio

Table 184 : Celltrion Inc.: News/Key Developments, 2023-2024

Table 185 : Coherus BioSciences: Company Snapshot

Table 186 : Coherus BioSciences: Financial Performance, FY 2022 and 2023

Table 187 : Coherus BioSciences: Product Portfolio

Table 188 : Coherus BioSciences: News/Key Developments, 2024

Table 189 : Fresenius Kabi AG: Company Snapshot

Table 190 : Fresenius Kabi AG: Financial Performance, FY 2022 and 2023

Table 191 : Fresenius Kabi AG: Product Portfolio

Table 192 : Fresenius Kabi AG: News/Key Developments, 2024

Table 193 : Lilly: Company Snapshot

Table 194 : Lilly: Financial Performance, FY 2022 and 2023

Table 195 : Lilly: Product Portfolio

Table 196 : Lilly: News/Key Developments, 2022-2023

Table 197 : Pfizer Inc.: Company Snapshot

Table 198 : Pfizer Inc.: Financial Performance, FY 2022 and 2023

Table 199 : Pfizer Inc.: Product Portfolio

Table 200 : Pfizer Inc.: News/Key Developments, 2023

Table 201 : Samsung Bioepis: Company Snapshot

Table 202 : Samsung Bioepis: Product Portfolio

Table 203 : Samsung Bioepis: News/Key Developments, 2023-2024

Table 204 : Sandoz Group AG: Company Snapshot

Table 205 : Sandoz Group AG: Financial Performance, FY 2022 and 2023

Table 206 : Sandoz Group AG: Product Portfolio

Table 207 : Sandoz Group AG: News/Key Developments, 2024

Table 208 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 209 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023

Table 210 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 211 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024

Table 212 : Viatris Inc.: Company Snapshot

Table 213 : Viatris Inc.: Financial Performance, FY 2022 and 2023

Table 214 : Viatris Inc.: Product Portfolio

Table 215 : Viatris Inc.: News/Key Developments, 2022

List of Figures

Summary Figure : Share of Global Market for Biosimilars, by Region, 2023

Figure 1 : Snapshot of the Market Dynamics for Biosimilars

Figure 2 : Share of Global Market for Biosimilars, by Product Type, 2023

Figure 3 : Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029

Figure 4 : Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029

Figure 5 : Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029

Figure 6 : Global Fusion Protein Biosimilars Market, by Region, 2021-2029

Figure 7 : Global Other Biosimilars Market, by Region, 2021-2029

Figure 8 : Share of Global Market for Biosimilars, by Therapeutic Application, 2023

Figure 9 : Global Cancer and Related Disorders Market in Biosimilars, 2021-2029

Figure 10 : Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029

Figure 11 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029

Figure 12 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029

Figure 13 : Global Diabetes Market in Biosimilars, 2021-2029

Figure 14 : Global Diabetes Market in Biosimilars, by Region, 2021-2029

Figure 15 : Global Anemia Market in Biosimilars, 2021-2029

Figure 16 : Global Anemia Market in Biosimilars, by Region, 2021-2029

Figure 17 : Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029

Figure 18 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029

Figure 19 : Global Other Diseases Market in Biosimilars, 2021-2029

Figure 20 : Global Other Diseases Market in Biosimilars, by Region, 2021-2029

Figure 21 : Share of Global Market for Biosimilars, by Region, 2023

Figure 22 : Global Biosimilars Market, by Region, 2021-2029

Figure 23 : Share of North American Market for Biosimilars, by Country, 2023

Figure 24 : U.S. Biosimilars Market, 2021-2029

Figure 25 : Canadian Biosimilars Market, 2021-2029

Figure 26 : Mexican Biosimilars Market, 2021-2029

Figure 27 : Share of European Market for Biosimilars, by Country, 2023

Figure 28 : German Biosimilars Market, 2021-2029

Figure 29 : U.K. Biosimilars Market, 2021-2029

Figure 30 : French Biosimilars Market, 2021-2029

Figure 31 : Italian Biosimilars Market, 2021-2029

Figure 32 : Spanish Biosimilars Market, 2021-2029

Figure 33 : Rest of European Biosimilars Market, 2021-2029

Figure 34 : Share of Asia-Pacific Market for Biosimilars, by Country, 2023

Figure 35 : Chinese Biosimilars Market, 2021-2029

Figure 36 : Japanese Biosimilars Market, 2021-2029

Figure 37 : Indian Biosimilars Market, 2021-2029

Figure 38 : Australian Biosimilars Market, 2021-2029

Figure 39 : South Korean Biosimilars Market, 2021-2029

Figure 40 : Rest of Asia-Pacific Biosimilars Market, 2021-2029

Figure 41 : Snapshot of the ESG Pillars

Figure 42 : Advantages of ESG for Biosimilar Companies

Figure 43 : Share of Biotech Companies Providing ESG Disclosure, 2022

Figure 44 : Share of ESG Disclosure, by Location, 2022

Figure 45 : Alvotech: Revenue Share, by Country/Region, FY 2023

Figure 46 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023

Figure 47 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023

Figure 48 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 49 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 50 : Biogen: Revenue Share, by Business Unit, FY 2023

Figure 51 : Biogen: Revenue Share, by Country/Region, FY 2023

Figure 52 : Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023

Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023

Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023

Figure 55 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023

Figure 56 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023

Figure 57 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023

Figure 58 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023

Figure 59 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 60 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023

Figure 61 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• がん免疫療法の技術と世界市場 2025-04-17
• 再生可能エネルギーの技術と世界市場 2025-04-17
• 木材・プラスチック複合材の技術と世界市場 2025-04-17
• 先端材料の調査レビュー　2024年 2025-04-16
• コールドチェーンの地域別市場分析：中東＆北アフリカ 2025-04-16

BCC Research  出版レポート一覧